97 related articles for article (PubMed ID: 10630245)
1. [Outpatient chemotherapy with infusional 5-fluorouracil in advanced gastrointestinal cancer].
Tsuji Y; Miyajima N; Kuroiwa G; Kato M; Nobuoka A; Ohi M; Honjo K
Gan To Kagaku Ryoho; 1999 Dec; 26 Suppl 2():346-50. PubMed ID: 10630245
[TBL] [Abstract][Full Text] [Related]
2. [Outpatient chemotherapy with continuous infusion of 5-fluorouracil (CI 5-FU) and intravenous bolus leucovorin (IVB LV) in advanced gastrointestinal cancer: the second report].
Tsuji Y; Yoshihito H; Nakamura T; Watanabe Y; Nakayama N; Ohi M; Kawanishi J; Handa H; Honjo K; Uehara S
Gan To Kagaku Ryoho; 1995 Dec; 22 Suppl 4():439-46. PubMed ID: 8849290
[TBL] [Abstract][Full Text] [Related]
3. [Outpatient chemotherapy with continuous infusion of 5-fluorouracil (CI 5-FU) and intravenous bolus leucovorin (IVB LV) in advanced gastrointestinal cancer].
Tsuji Y; Nakamura T; Katagiri E; Kawanishi J; Handa H; Honjo K; Uehara S; Izumiyama S; Hirayama A; Sagawa T
Gan To Kagaku Ryoho; 1994 Dec; 21 Suppl 4():419-25. PubMed ID: 7802444
[TBL] [Abstract][Full Text] [Related]
4. [Outpatient chemotherapy with weekly high-dose infusional 5-fluorouracil (weekly HD-FU) in advanced gastrointestinal cancer].
Tsuji Y; Kuroiwa G; Kato M; Ohi M; Handa H; Honjo K; Uehara S; Hirayama A
Gan To Kagaku Ryoho; 1998 Dec; 25 Suppl 4():619-24. PubMed ID: 9884653
[TBL] [Abstract][Full Text] [Related]
5. Paclitaxel and leucovorin-modulated infusional 5-fluorouracil combination chemotherapy for metastatic gastric cancer.
Cho BC; Kim JH; Kim CB; Sohn JH; Choi HJ; Lee YC; Ahn JB
Oncol Rep; 2006 Mar; 15(3):621-7. PubMed ID: 16465422
[TBL] [Abstract][Full Text] [Related]
6. [Outpatient chemotherapy with continuous intravenous infusion for patients with recurrent renal cell carcinoma or advanced prostate carcinoma].
Otsuka A; Ono S; Hata M; Ota N
Gan To Kagaku Ryoho; 1997 Dec; 24 Suppl 4():485-9. PubMed ID: 9429553
[TBL] [Abstract][Full Text] [Related]
7. [Ambulatory and domiciliary cancer chemotherapy with forearm implant catheter system and low-dose CDDP + 5-FU therapy].
Tsuji A; Morita S; Horimi T; Takasaki M; Takahashi I; Shirasaka T
Gan To Kagaku Ryoho; 1999 Dec; 26 Suppl 2():326-32. PubMed ID: 10630242
[TBL] [Abstract][Full Text] [Related]
8. Biweekly oxaliplatin plus 1-day infusional fluorouracil/leucovorin followed by metronomic chemotherapy with tegafur/uracil in pretreated metastatic colorectal cancer.
Lin PC; Chen WS; Chao TC; Yang SH; Tiu CM; Liu JH
Cancer Chemother Pharmacol; 2007 Aug; 60(3):351-6. PubMed ID: 17111120
[TBL] [Abstract][Full Text] [Related]
9. Biweekly oxaliplatin, fluorouracil and leucovorin versus cisplatin, fluorouracil and leucovorin in patients with advanced gastric cancer.
Popov I; Radosevic-Jelic L; Jezdic S; Milovic M; Borojevic N; Stojanovic S; Stankovic V; Josifovski T; Kezic I
J BUON; 2008; 13(4):505-11. PubMed ID: 19145671
[TBL] [Abstract][Full Text] [Related]
10. Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer.
Hochster H; Chachoua A; Speyer J; Escalon J; Zeleniuch-Jacquotte A; Muggia F
J Clin Oncol; 2003 Jul; 21(14):2703-7. PubMed ID: 12860947
[TBL] [Abstract][Full Text] [Related]
11. 5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer.
Sobrero A; Guglielmi A; Cirillo M; Recaldin E; Frassineti GL; Aschele C; Ravaioli A; Testore P; Caroti C; Gallo L; Pessi MA; Cortesi E; Turci D; Grossi F; Labianca R
Br J Cancer; 2001 Apr; 84(8):1023-8. PubMed ID: 11308248
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial.
Cascinu S; Labianca R; Barone C; Santoro A; Carnaghi C; Cassano A; Beretta GD; Catalano V; Bertetto O; Barni S; Frontini L; Aitini E; Rota S; Torri V; Floriani I; ; Pozzo C; Rimassa L; Mosconi S; Giordani P; Ardizzoia A; Foa P; Rabbi C; Chiara S; Gasparini G; Nardi M; Mansutti M; Arnoldi E; Piazza E; Cortesi E; Pucci F; Silva RR; Sobrero A; Ravaioli A
J Natl Cancer Inst; 2007 Apr; 99(8):601-7. PubMed ID: 17440161
[TBL] [Abstract][Full Text] [Related]
13. Weekly infusional high-dose fluorouracil (HD-FU), HD-FU plus folinic acid (HD-FU/FA), or HD-FU/FA plus biweekly cisplatin in advanced gastric cancer: randomized phase II trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie.
Lutz MP; Wilke H; Wagener DJ; Vanhoefer U; Jeziorski K; Hegewisch-Becker S; Balleisen L; Joossens E; Jansen RL; Debois M; Bethe U; Praet M; Wils J; Van Cutsem E; ;
J Clin Oncol; 2007 Jun; 25(18):2580-5. PubMed ID: 17577037
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
Hsu CH; Cheng AL; Hsu C; Yang CH; Lu YS; Lin CC; Bu CF; Yeh KH
Anticancer Res; 2002; 22(6B):3621-7. PubMed ID: 12552966
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II study of oxaliplatin with weekly bolus fluorouracil and high-dose leucovorin (ROX) as first-line therapy for patients with colorectal cancer.
Yamada Y; Ohtsu A; Boku N; Miyata Y; Shimada Y; Doi T; Muro K; Muto M; Hamaguchi T; Mera K; Yano T; Tanigawara Y; Shirao K
Jpn J Clin Oncol; 2006 Apr; 36(4):218-23. PubMed ID: 16684860
[TBL] [Abstract][Full Text] [Related]
16. Safety of cisplatin combined with continuous 5-FU versus bolus 5-FU and leucovorin, in metastatic gastrointestinal cancer (FFCD 9404 randomised trial).
Duffour J; Bouché O; Rougier P; Milan C; Bedenne L; Seitz JF; Buecher B; Legoux JL; Ducreux M; Vetter D; Raoul JL; François E; Ychou M
Anticancer Res; 2006; 26(5B):3877-83. PubMed ID: 17094417
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of weekly oxaliplatin and high-dose infusional 5-fluorouracil plus leucovorin in pretreated patients with metastatic colorectal cancer.
Chiara S; Nobile MT; Gozza A; Taveggia P; Heouaine A; Pastrone I; Percivale PL; Lionetto R; Sanguineti O; Rosso R
Anticancer Res; 2004; 24(1):355-60. PubMed ID: 15015621
[TBL] [Abstract][Full Text] [Related]
18. Treatment outcomes of oxaliplatin, 5-FU, and leucovorin as salvage therapy for patients with advanced or metastatic gastric cancer: a retrospective analysis.
Seo HY; Kim DS; Choi YS; Sung HJ; Park KH; Choi IK; Kim SJ; Oh SC; Seo JH; Choi CW; Kim BS; Shin SW; Kim YH; Kim JS
Cancer Chemother Pharmacol; 2009 Feb; 63(3):433-9. PubMed ID: 18398608
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of oxaliplatin with low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) as first line therapy for patients with advanced gastric cancer.
Oh SY; Kwon HC; Seo BG; Kim SH; Kim JS; Kim HJ
Acta Oncol; 2007; 46(3):336-41. PubMed ID: 17450469
[TBL] [Abstract][Full Text] [Related]
20. Palliative second-line treatment with weekly high-dose 5-fluorouracil as 24-hour infusion and folinic acid (AIO) plus oxaliplatin after pre-treatment with the AIO-regimen in colorectal cancer (CRC).
Link K; Happich K; Schirner I; Jüngert B; Brückl V; Männlein G; Brückl WM; Merkel S; Göhl J; Hohenberger W; Hahn EG; Wein A
Anticancer Res; 2004; 24(1):385-91. PubMed ID: 15015625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]